Companies › OHB Neonatology
1 active drug program in 1 registered trial: 1 Phase 2; Cardiovascular; next expected readout Jan 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Mecasermin Rinfabate (OHB-607) Insulin-like growth factor I receptor agonist | IGF1R | Phase 2 | Bronchopulmonary Dysplasia | Jan 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03253263 | Mecasermin Rinfabate (OHB-607) | Phase 2 | Bronchopulmonary Dysplasia | Cardiovascular | Jan 2028 |
Innovent Biologics (Suzhou) Amgen Candid Therapeutics Viridian Therapeutics Minghui Pharmaceutical (Hangzhou) Sling Therapeutics Zai Lab (Shanghai)
Merakris Therapeutics Arch Biopartners Tectonic Operating Company CuraSen Therapeutics Neurimmune
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.